Hefei Science Island team cracks the difficult problem of detecting paclitaxel resistance in breast cancer.

Recently, the research team led by Wang Hongzhi at the Hefei Institutes of Physical Science, Chinese Academy of Sciences/ Hefei Cancer Hospital made important progress in the sensitivity research of paclitaxel treatment for breast cancer. The team successfully developed a programmable plasma ring biosensor called MetaRing, which can quickly, conveniently, and accurately determine the sensitivity of breast cancer patients to the commonly used chemotherapy drug paclitaxel. This technology is expected to provide new technical support for solving the challenges in clinical chemotherapy caused by individual differences in patients and tumor heterogeneity. The related research findings were published in Biosensors and Bioelectronics.